ClinicalTrials.Veeva

Menu
T

The Skin Centre | Benowa, Australia

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

PEP005
PF-04965842
PF-06651600
Rocatinlimab
Ingenol Mebutate
LY3009104
Baricitinib
BMS-986165
Pf-04965842
CNTO 1959

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 39 total trials

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo an...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with at...

Enrolling
Atopic Hand and Foot Dermatitis
Drug: Lebrikizumab
Drug: Placebo

This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescen...

Active, not recruiting
Alopecia Areata
Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine

The main purpose of this study is to evaluate the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in participants who have bee...

Active, not recruiting
Psoriasis
Drug: Placebo
Drug: BMS-986165

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Trial sponsors

Pfizer logo
P
Lilly logo
Amgen logo
Bristol-Myers Squibb (BMS) logo
D
Janssen (J&J Innovative Medicine) logo
AbbVie logo
B
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems